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Sirtuin 1 (SIRT1) enzyme plays a pivotal role in the regulation of many physiological functions. In particular, it is implicated in ageing-
related diseases, such as cardiac hypertrophy,myocardial infarct, and endothelial dysfunction;moreover, its expression decreases with age.
Therefore, an eﬀective strategy to extend the lifespan and improve cardiovascular function is the enhancement of the expression/activity
of SIRT1 with exogenous agents. The Citrus ﬂavonoid naringenin (NAR) presents structural similarity with the natural SIRT1 activator
resveratrol. In this study, we demonstrate through in vitro assays that NAR signiﬁcantly activates SIRT1 enzyme and shows
antisenescence eﬀects. The binding mode of NAR into SIRT1 was detailed investigated through in silico studies. Moreover, chronic
administration (for six months) of NAR (100mg/kg/day) to 6-month-old mice leads to an enhancement of SIRT1 expression and a
marked reduction of reactive oxygen species production in myocardial tissue. Furthermore, at the end of the treatment, the plasma
levels of two well-known markers of cardiovascular inﬂammation, TNF-α and IL6, are signiﬁcantly reduced in 12-month-old
mice treated with NAR, as well as the cardiovascular risk (total cholesterol/HDL ratio) compared to control mice. Finally, the
age-associated ﬁbrotic remodeling, which is well detected through a Mallory trichrome staining in the vehicle-treated 12-month-
old mice, is signiﬁcantly reduced by the chronic treatment with NAR. Moreover, an improvement of myocardium functionality
is highlighted by the enhancement of citrate synthase activity and stabilization of the mitochondrial membrane potential after
NAR treatment. Taken together, these results suggest that a nutraceutical approach with NAR may have positive impacts on
many critical hallmarks of myocardial senescence, contributing to improve the cardiac performance in aged subjects.
1. Introduction
Ageing is a physiological process associated with a progressive
impairment of homeostasis at cellular, tissue, and systemic
level that increases the susceptibility to several ageing-
related diseases. In this context, the heart is one of the main
organs at risk; indeed, myocardial remodeling, accompanied
by collagen ﬁber deposition, is considered the gateway to
severe cardiac diseases, such as ﬁbrosis and myocardial
hypertrophy and heart failure [1].
In this scenario, oxidative stress plays a critical role. Since
mitochondria are the main source of reactive oxygen species
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(ROS), the oxidative stress condition, typical of ageing, can
be considered as a consequence of the decline of the mito-
chondrial bioenergetics. On the other hand, the high age-
related production of ROS is also responsible for worsening
of its own functionality [2]. Moreover, an age-related low-
grade chronic inﬂammation, deﬁned inﬂammaging, has
been described [3]. In this regard, macrophages are a key
source of proinﬂammatory molecules, such as tumor necro-
sis factor- (TNF-) α, interleukin (IL) 6, and matrix metallo-
proteinases (MMPs), responsible in turn for the persistence
of the basal inﬂammatory response [4].
Moreover, also sirtuin 1 (SIRT1) enzyme, a type III
histone deacetylase able to regulate a plethora of intracellular
signaling proteins, is implicated in ageing-related diseases,
such as cardiac hypertrophy, myocardial infarct, and endothe-
lial dysfunction. Noteworthly, SIRT1 protects against endo-
thelial dysfunction [5, 6] and slows down the progression of
cardiovascular senescence [7]. Furthermore, its expression/-
activity is inversely related with ischemia-reperfusion dam-
age or with severity of heart failure [8, 9].
The expression of SIRT1 enzyme gradually decreases with
age, and SIRT1-deﬁcient mice show a reduced lifespan [10].
Therefore, considering that ageing is a complex multifac-
torial process and the maintenance of the cell homeostasis is
relevant for the preservation of a healthy state, many eﬀorts
are being made to identify natural and synthetic compounds
eﬀective on these potential targets.
Naringenin (NAR), a ﬂavanone typical of Citrus fruits,
seems to be a promising candidate. Indeed, previous studies
demonstrated its beneﬁcial cardiovascular activities, both as
vasorelaxing and cardioprotective agent [11–14]. Moreover,
we recently observed that NAR also exerts antisenescence
eﬀects. In particular, in H9c2 cardiomyoblasts submitted to
oxidative stress by H2O2 treatment, NAR contained the β-
galactosidase activity, as well as the expression of p21 and
p16, well-known markers of ageing [15]; furthermore, berga-
mot juice, containing a high amount of NAR, increased the
genic expression of the antiageing markers SIRT1, Nrf2,
and FOXO1 in cardiac tissues [16]. Noteworthly, NAR
exhibits close structural analogies with well-known SIRT1
activators, such as such as resveratrol (RES) and quercetin
[17–20]. Therefore, we hypothesize that NAR can possess
an interesting antisenescence SIRT1-mediated proﬁle, useful
as nutraceutical tool in humans. In this work, we investigated
the eﬀects of chronic administration of NAR on myocardial
ageing using an in vivo approach in mice.
2. Materials and Methods
2.1. Activation of SIRT1 In Vitro. The eﬀects of NAR (pur-
chased as pure compound from Sigma-Aldrich, USA) 10,
30, 100, and 300μM on SIRT1 activity were evaluated by a
direct enzymatic assay using a SIRT1 Direct Fluorescent
Screening Assay Kit (Cayman Chemical, USA), following
the protocol user guide. Fluorescence was analyzed with the
EnSpire spectroﬂuorometer (PerkinElmer, USA) at a wave-
length of 350-360nm in excitation and 450-465 nm in emis-
sion. The increase in recorded ﬂuorescence was directly
proportional to the activation of SIRT1.
Data analysis. Data obtained were analyzed by removing
baseline and normalizing to the ﬂuorescence value of the
vehicle (0%) and the SIRT1 activator resveratrol (RES,
Sigma-Aldrich, USA) 100μM (100%). One-way ANOVA
followed by Bonferroni’s post hoc test was selected as statis-
tical analysis, and the diﬀerence between groups was consid-
ered statistically diﬀerent when p < 0:05.
2.2. Computational Study about the Activation of SIRT1 by
NAR. The calculation was performed on a system comprising
56 Intel Xeon E5-2660 v4@2.00GHz processors and two
NVIDIA GeForce RTX 2070 GPU, running Maestro Molec-
ular Modeling environment release 2018 (Schrödinger, LLC,
New York, NY, 2018).
2.2.1. Computational Details. Molecule preparation. The
three-dimensional structures of the NAR and RES were
downloaded by PubChem and imported into Maestro. Sub-
sequently, energy minimization of conformers was achieved
by means of MacroModel software (MacroModel, Schrödin-
ger, LLC, New York, NY, 2018) as reported by us [21, 22],
employing the OPLS-AA 2005 as force ﬁeld and GB/SA
model for simulating the solvent eﬀects. PRCG method with
1000 maximum iterations and 0.001 gradient convergence
threshold was employed. Furthermore, LigPrep (LigPrep,
Schrödinger, LLC, New York, NY, 2018) was employed in
order to reﬁne the chemical structures.
Protein preparation. SIRT1 three-dimensional structure
in complex with RES was downloaded from Protein Data
Bank (PDB) (PDB ID: 5BTR [23]) and submitted to the pro-
tein preparation wizard protocol implemented in Maestro
suite 2018 (Protein Preparation Wizard workﬂow 2018) in
order to obtain a reasonable starting structure for performing
in silico studies [21, 24].
Molecular docking. Docking experiments were performed
by Glide (Schrödinger, LLC, New York, NY, 2018) using the
ligands and the protein prepared as mentioned above
employing Glide extra precision (XP) method as scoring
function. The energy grids were prepared using the default
value of the protein atom scaling factor (1.0Å) within a cubic
box centered on the crystallized RES molecules. After grid
generation, the ligands (NAR and RES) were docked into
the enzymes considering the three diﬀerent potential binding
sites of RES. The number of poses entered to postdocking
minimization was set to 1000, and the Glide XP score was
evaluated. The XP method was able to correctly accommo-
date the RES into the three binding sites (data not shown).
2.3. In Vitro Antisenescence Activity
2.3.1. Cell Culture. H9c2 cells are commonly used as a suc-
cessful cellular model for studies of myocardial ageing [13,
15, 16]. H9c2 cells (ATTC, USA) were cultured in DMEM
high glucose, supplemented with 10% FBS, 100 units/mL
penicillin, and 100mg/mL streptomycin in tissue culture
ﬂasks at 37°C in a humidiﬁed atmosphere of 5% CO2.
2.3.2. Senescence-Associated β-Galactosidase Staining. H9c2
cardiomyocytic cells were treated with hydrogen peroxide
(H2O2) in order to induce cellular senescence, as previously
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reported [15, 16, 25, 26]. Cells were seeded onto 24-well
plates (10 × 103 cells/cm2), and after 24 h, cells received
H2O2 (60μM) treatment or relative vehicle (distilled water)
for 3 h. Then, the medium was replaced with fresh medium
containing NAR, 40μM, RES (25μM), sirtinol, a selective
SIRT 1 blocker (SIR, 20μM), alone or in combination with
NAR or RES, and relative control (0.01% DMSO). After 72
hours, the sa-β-Gal staining was assessed [16], ﬁxing the cells
in p-formaldehyde and incubating them in staining solution
for 16 h at 37°C. Following phosphate-buﬀered saline wash-
ing, images of cells by light microscopy were captured (10x
magniﬁcation, 5 random ﬁelds per well), and both blue and
total cells were counted using ImageJ (ImageJ Software, ver-
sion 1.41, USA).
2.4. In Vivo Chronic Treatment. Male six-month-old
C57BL/6J mice (ENVIGO, Milan, Italy) were randomly
assigned into two diﬀerent groups: one was daily treated with
NAR (100mg/kg) diluted in water while the other one was
treated with vehicle (DMSO 1%) up to twelve months of
age. Untreated three-month-old mice were used as young
controls. The diluted solutions were daily prepared; more-
over, mice were weekly weighted, and water intake was daily
monitored during the six-month treatment. The dosage of
NAR (100mg/kg) has been selected based on previous
in vivo experiments [13, 27] and in accordance with papers
of others [28–31]. In particular, NAR has been dissolved in
DMSO 40mg/mL and diluted in water up to 0.4mg/mL, to
assure a daily dosage of 100mg/kg.
All procedures were performed according to European
(EEC Directive 2010/63) and Italian (D.L. 4 March 2014
n.26) legislation. Experiments have been reported according
to the ARRIVE guidelines [32]. Animals were housed in cages
with free access to standard food pellets and water under stan-
dard conditions (12-hour light/dark cycle, 22°C). At the end of
treatment, mice were anesthetized with an aqueous solution of
urethane (30% w/w), i.p. (Sigma-Aldrich, USA); then, blood
was collected and the heart explanted to functional, histologi-
cal, and biochemical analysis.
2.4.1. Measurement of Lipid and Glucose Levels in Blood. At
the end of the treatment, blood was collected from the tail
tip of each mouse and fasting blood glucose levels were deter-
mined using Glucocard™ blood glucose meter (Menarini,
Italy). Then, animals were anaesthetized with an intraperito-
neal injection of aqueous urethane solution 30% w/w. Intra-
cardiac blood was collected in tubes with the anticoagulant
EDTA (BD Vacutainer), and complete lipid panel (triglycer-
ides, total cholesterol, HDL, and LDL) and glycated haemo-
globin levels were measured with Cobas b 101 instrument
(Roche Diagnostics, Switzerland).
Data analysis. Blood samples were collected from 15mice
per group and results were expressed as mean ± SEM. Car-
diovascular risk was expressed as ratio between total choles-
terol and HDL cholesterol levels. One-way ANOVA
followed by Bonferroni’s post hoc test was selected as statis-
tical analysis, and the diﬀerence between groups was consid-
ered statistically diﬀerent when p < 0:05.
2.4.2. Cardiac Mitochondria Isolation. Hearts were explanted
and immediately put in an ice-cold isolation buﬀer (com-
position: sucrose 250mM, Tris 5mM, EGTA 1mM, pH
7.4). The ventricular tissue has been rapidly cut and
homogenized with an Ultra-Turrax homogenizer (IKA-
Werke GmbH & Co., Germany); three homogenization
cycles on ice were performed. Then, the suspension was
centrifuged at 1075×g for 3 minutes at 4°C (EuroClone,
Speed Master 14 R centrifuge, Italy), and the resulting
supernatant was centrifuged at 11950×g for 10 minutes
at 4°C. The pellet was resuspended in an isolation buﬀer
without EGTA and centrifuged at 11950×g for 10 minutes
at 4°C. Finally, the mitochondrial pellet was suspended in
the isolation buﬀer without EGTA and stored on ice during
the experiment. Mitochondrial protein concentration was
determined by Bradford assay. All reagents were purchased
from Sigma-Aldrich, USA.
Measurement of Mitochondrial Membrane Potential (ΔΨ).
Mitochondrial membrane potential was evaluated with a
potentiometric method, using a tetraphenylphosphonium-
(TPP+-) sensitive minielectrode and a reference electrode
(WPI, USA), both connected with a data acquisition soft-
ware (Biopac Inc., USA). Firstly, known concentrations of
TPP+Cl- (Sigma-Aldrich, USA) were used to calibrate the
electrodes. Then, mitochondria (1mg protein/mL) were
added to the incubation buﬀer (composition: KCl 120mM,
K2HPO4 5mM, Hepes 10mM, succinic acid 10mM, MgCl2
2mM, TPP+Cl- 10μM, pH 7.4), and they were continuously
stirred with a small magnet to generate a mitochondrial
suspension.
Data analysis. Mitochondrial membrane potential was
calculated by a modiﬁed Nernst experimental equation (1):
ΔΨ = 60x log V0 · TPP½ 
+/ TPP½ +ð Þ −Vt − K0P
VmP + KiP
, ð1Þ
where ΔΨ is the mitochondrial membrane potential (mV),
V0 is the volume of the incubation buﬀer before the addition
of mitochondria, Vt is the volume of the incubation buﬀer
after the addition of mitochondria, Vm is the volume of
mitochondrial matrix (taken as 1μL/mg of proteins), TP
P+0 is the concentration of TPP+ recorded before the addi-
tion of mitochondria while TPP+t is the concentration of
TPP+ recorded at time t, K0 and Ki are apparent external
and internal partition coeﬃcients of TPP+ (14.3μL/mg and
7.9μL/mg, respectively), and P is the protein concentration
(expressed in mg).
The mitochondrial membrane potential was evaluated on
6 diﬀerent animals per group, and data were expressed as
mean ± SEM. One-way ANOVA followed by Bonferroni’s
post hoc test was used to compare groups for statistical diﬀer-
ences (p < 0:05).
Measurement of Mitochondrial Citrate Synthase Activity.
Mitochondria were diluted in Tris buﬀer 100mM (pH 8.2)
containing 5,5′-dithiobis-(2-nitrobenzoic) acid (DTNB,
100μM) and Acetyl Coenzyme A (100μM); then, they were
treated with Triton X-100 (0,02% v/v) for 5′ at room temper-
ature to lyse mitochondrial membranes, thus releasing citrate
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synthase enzyme. The assay was performed in multiwell
plates, and the reaction was initiated by the addition of oxal-
acetate 500μM. Absorption was measured spectrophotomet-
rically at 30°C and 412nm every 15 seconds for 3 minutes
using a microplate reader (EnSpire, PerkinElmer, USA). All
reagents were purchased from Sigma-Aldrich, USA.
Data analysis. Mitochondrial citrate synthase activity was
determined by comparison to a calibration curve obtained
with known concentrations of the enzyme. Cardiac mito-
chondria were isolated from the hearts of 8 animals per
group, and they were expressed as mean ± SEM. One-way
ANOVA followed by Bonferroni’s post hoc test was selected
as statistical analysis, and the diﬀerence between groups was
considered statistically diﬀerent when p < 0:05.
2.4.3. Western Blot Analysis of SIRT1 Enzyme. A portion of
the left ventricular tissue was lysed in RIPA buﬀer, and pro-
teins were quantiﬁed with the Bradford assay (Bio-Rad,
USA). Proteins (25μg) were separated onto a precast 4-20%
polyacrylamide gel (Mini-PROTEAN® TGX gel, Bio-Rad,
USA) and transferred to PVDF membranes (Trans-Blot®
Turbo™ PVDF Transfer packs, Bio-Rad, USA). Membranes
were blocked with 5% bovine serum albumin (BSA) diluted
in Tris-buﬀered saline (TBS, 20mM Tris-HCl, pH 7.5,
150mM NaCl) with 0.1% Tween 20. Primary antibodies
against GAPDH (1 : 5000, Millipore) and SIRT1 (1 : 100, Santa
Cruz, USA) were incubated overnight at 4°C. Then, mem-
branes were incubated with secondary antibodies (1 : 5000,
anti-mouse and anti-rabbit) for 2h at room temperature.
The immunoblot signal was visualized by using enhanced
chemiluminescence substrate detection system (Luminata™
Forte Western HRP Substrate, Millipore, USA). The chemi-
luminescent images were acquired by LAS4010 (GE Health-
care Life Sciences, USA). Densitometry was undertaken
using ImageJ software.
Data analysis. One-way ANOVA followed by Bonferro-
ni’s post hoc test was selected as statistical analysis, and the
diﬀerence between groups was considered statistically diﬀer-
ent when p < 0:05.
2.4.4. RNA Extraction and Real-Time PCR Analysis on
SIRT1. The total RNA from a portion of the left ventricular
tissue was extracted using the RNeasy® Mini Kit (Qiagen,
Germany), determining the purity of the RNA samples by
measuring the absorbance at 260 : 280 nm. cDNA synthesis
was performed with 500ng of RNA using the iScript cDNA
synthesis kit (Bio-Rad, Hercules, USA). SIRT1 and GAPDH
primers were designed in intron/exon boundaries (SIRT1:
For: ATGACGCTGTGGCAGATTGTT and Rev: CCGCAA
GGCGAGCATAGAT; GAPDH: For: ATGTGTCCGTCG
TGGATCTGAC and Rev: AGACAACCTGGTCCTCAGT
GTAG) [16]. RT-PCR reactions consisted of 25μL Fluo-
Cycle® II SYBR® (EuroClone, Italy), 1.5μL of both 10μM
forward and reverse primers for SIRT1 and GAPDH
(Sigma-Aldrich, Italy), 3μL cDNA, and 19μL of H2O. All
reactions were performed for 38 cycles using the following
temperature proﬁles: 94°C for 30 s (initial denaturation);
annealing temperature 90°C for 30 s (annealing); and 72°C
for 1 s (extension). GAPDH was used as the housekeeping
gene. mRNA levels were normalized against GAPDHmRNA
levels, and relative expression was calculated by using the Ct
value. PCR speciﬁcity was determined by both the melting
curve analysis and gel electrophoresis.
Data analysis. One-way ANOVA followed by Bonferro-
ni’s post hoc test was selected as statistical analysis, and the
diﬀerence between groups was considered statistically diﬀer-
ent when p < 0:05.
2.4.5. Detection of Oxidative Stress. For histological labeling
and qualitative image acquisition, left ventricles from mice
were isolated and readily included in Optimal Cutting Tem-
perature (OCT, Japan) without ﬁxation. Cryosection 20μm
thick was obtained using a manual cryostat (Leica, Germany)
and collected onto glass slides. Ventricle sections were then
incubated in 10μM dihydroethidium (DHE) solution at
37°C for 30min. Sections were then rinsed 3 × 5 min in
phosphate-buﬀered saline (PBS) and mounted for ﬂuores-
cent imaging with Vectashield (Vector, Burlingame). Images
were obtained for each section using a 20x objective (NA
0.50) on a Nikon Ni-E microscope (Nikon Instruments,
Italy). In order to quantify ROS-positive areas in the diﬀerent
experimental groups, six ﬁelds of each section of the left ven-
tricle were acquired and analyzed. Three sections for each left
ventricle of ﬁve animals per group were sampled.
2.4.6. Inﬂammatory Markers. The cardiac tissue was reduced
to powder in liquid N2, then homogenized in PBS with an
ultrasonic homogenizer (Braun, Germany) and centrifuged
at 14000 rpm for 10 minutes at 4°C. The supernatant was
used for the test. The concentration of total proteins in the
supernatant was measured using the protein quantiﬁcation
assay of bicinchoninic acid (Sigma-Aldrich, USA). The con-
centrations of TNF-α and IL6 were measured in myocardial
tissue using an ELISA commercial kit (R&D Systems, USA).
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Figure 1: The histogram shows the % of ﬂuorescence emitted (vs.
RES 100μM) following the incubation of NAR 10, 30, 100, or
300μM with isolated and puriﬁed SIRT1 enzyme. The bars are
expressed as average ± SEM. Statistical analysis is one-way ANOVA
followed by Bonferroni’s multiple comparison test (∗p < 0:05; ∗∗∗p
< 0:001).
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Data analysis. One-way ANOVA followed by Bonferro-
ni’s post hoc test was selected as statistical analysis, and the
diﬀerence between groups was considered statistically diﬀer-
ent when p < 0:05.
2.4.7. Histological Evaluation of Fibrosis. Histological evalua-
tion of ﬁbrosis was performed on 20 male mice belonging to
4 groups (5 per group): (1) three-month-old untreated, (2)
six-month-old untreated, (3) twelve-month-old untreated,
and (4) twelve-month-old treated. At necropsy, heart ven-
triculi were collected and referred to the histology labora-
tory. Samples were paraﬃn embedded and sectioned to
show both ventricular walls. After rehydration of sections,
Mallory trichrome staining was performed by using a com-
mercial kit (04-020802, Mallory trichrome, Bio Optica,
Italy); slides were thus dehydrated, cleared, and mounted
with permanent mounting medium. Five images at 20x mag-
niﬁcation were collected focusing at connective tissue hot
spots and semiautomatically analyzed with the image pro-
cessing software Nis-Elements Br (Nis-Elements Br, Nikon
Instruments, Italy). Fibrosis was expressed as percent of
the images occupied by the connective tissue (stained in blue
with Mallory trichrome).
Data analysis. Values were analyzed by Bonferroni’s mul-
tiple comparison test as post hoc analysis after one-way anal-
ysis of variance; signiﬁcance was set at p < 0:05.
2.4.8. Evaluation of Cardiac Tissue miR-214-3p Expression.
Total microRNAs from frozen cardiac tissue were extracted
and reverse transcripted by using miRNeasy Mini Kit and
miScript Reverse Transcription Kit (Qiagen, Germany),
respectively. Quantitative PCR was performed using the miS-
cript SYBR-Green PCR Kit and MiScript Primer Assays spe-
ciﬁc for mmu-miR-214-3p (MIMAT0000661) and mmu-
SNORD6 (Qiagen, Germany), as previously reported [33,
34]. miRNA expression was calculated using Ct method
and normalized to the expression of housekeeping SNORD6.
Data analysis. Data were represented as themean ± SEM.
Comparisons of results were carried out by t-test. A p value <
0.05 was considered as statistically signiﬁcant.
3. Results
3.1. In Vitro SIRT1 Enzyme Activity and In Silico Study of
NAR as Activator of SIRT1. NAR was incubated with the iso-
lated and puriﬁed SIRT1 enzyme at 10, 30, 100, and 300μM,
(a) (b)
(c) (d)
Figure 2: (a) SIRT1 (light grey cartoon) cocrystallized with RES (sticks representation) (PDB ID: 5BTR). In the picture was highlighted the
three diﬀerent binding sites of RES (#site1 is represented in cyan; #site2 is represented in magenta, while #site3 is represented in orange). The
signiﬁcant residues in the binding sites are represented by lines. (b) Putative binding mode of NAR (represented by light blue sticks) into
#site1. The interacting residues of the binding site are labeled. (c) Putative binding mode of NAR (represented by light blue sticks) into
#site2. The interacting residues of the binding site are labeled. (d) Putative binding mode of NAR (represented by light blue sticks) into
#site3. The binding site interacting residues are labeled. The acetylated p53-AMC peptide is represented by green sticks. The H-bonds are
represented by dark grey dotted lines. The pictures were generated by PyMOL (The PyMOL Molecular Graphics System, v1.8;
Schrödinger, LLC, New York, 2015).
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instead RES, the reference compound, was administrated at
100μM. NAR concentration-dependently stimulated the
SIRT1 enzyme activity, leading to a signiﬁcant activation of
24 ± 4% at 100μM and to 55 ± 2% at 300μM (Figure 1).
In order to gain insight into the interaction of NAR
within the enzyme SIRT1 at molecular level, we performed
a computational investigation based on the application of a
molecular docking protocol. This calculation was done as
described in Materials and Methods. In particular, due to
the high similarity of NAR with RES, it is plausible to hypoth-
esize that the mentioned molecules could share the same
binding mode. The results in Figure 1 showed that NAR
behaves as activator of SIRT1 as observed for RES. Concisely,
RES is able to activate SIRT1 by interacting with a speciﬁc
region of the N-terminal domain (NTD) of SIRT1. In par-
ticular, as depicted in Figure 2(a), the crystal structure
revealed that three molecules of RES are able to bind the
mentioned domain in three distinct regions of the NTD
[23], namely, #site1, #site2, and #site3. In addition, the
experimental structure of RES in complex with SIRT1 was
Control
(a)
H2O2
(b)
H2O2+NAR
(c)
H2O2+RES
(d)
H2O2+SIR
(e)
H2O2+NAR+SIR
(f)
H2O2+RES+SIR
(g)
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Figure 3: Eﬀects of NAR on H9c2 senescence-associated β-galactosidase staining. Representative phase-contrast photomicrographs of
control cells (a), H2O2-injured cells (b), H2O2-injured cells treated with NAR 40 μM (c) or RES 25 μM (d) or SIR 20 μM (e), and H2O2-
injured cells treated with NAR plus SIR (f) or RES plus SIR (g). (h) Histogram shows the percentage of cellular senescence. Data are
shown as the percentages of β-galactosidase-positive cells with respect to the total cell number of the sample. Each bar represents the
mean ± SEM. Statistical analysis is one-way ANOVA followed by Bonferroni’s multiple comparison test (∗∗∗p < 0:001). ∗Indicates the
signiﬁcance versus control; °indicates the signiﬁcance versus H2O2-injured cells.
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obtained with a peptide sequence (7-amino-4-methylcou-
marin AMC-containing peptide), representing the p53-
interacting residues and located at the interface between
NTD and catalytic domain (CD) (Figure 2(a)). The above-
mentioned binding sites were found to diﬀerently contribute
to the activation of SIRT1. Two molecules of RES mediate
the interaction between the AMC peptide and the NTD of
SIRT1 and are principally responsible for promoting tighter
binding between SIRT1 and the peptide and consequently
the stimulation of SIRT1 activity. Notably, this kind of con-
dition is the same with that used in the assay for assessing
the activation of SIRT1 as reported in the previous para-
graph. As experimentally demonstrated, NAR and RES
act as SIRT1 activators with diﬀerent potency. So, due to
the high similarity between the molecules, by a computa-
tional analysis, it is possible to rationalize this phenomenon.
We independently docked NAR and RES at the three binding
sites for evaluating the binding aﬃnity. Starting from the
#site1, we observed that NAR and RES established a series
of contacts with the enzyme (H-bonds with E230) and also
with the AMC peptide (H-bonds with Lys3 and hydrophobic
interactions with AMC moiety) (Figures 2(a) and 2(b)). We
found a binding aﬃnity of -6.132 kcal/mol for NAR and
-7.127 kcal/mol for RES which was observed to establish
more relevant hydrophobic contacts within the #site1.
Regarding the #site2, NAR targets key residues in activat-
ing SIRT1 (Q222 and N226) (Figure 2(c)). An H-bond was
observed with the backbone of Arg1 of the AMC peptide.
NAR showed a binding aﬃnity for this site of -6.146 kcal/mol
while RES of -7.159 kcal/mol. The above described binding
sites were found extremely relevant in activating SIRT1,
while the third site is deﬁned as “accessory site,” showing a
poorer contribution in activating SIRT1 [23]. In this binding
site, the aﬃnity found for NAR is -6.179 kcal/mol while for
RES it is -7.204 kcal/mol. In summary, based on the compu-
tational investigation, the before binding mode of NAR could
be the same described for RES. In fact, signiﬁcant aﬃnities
were found for NAR towards the three binding sites, suggesting
that the compound can bind the same binding sites of RES.
The latter is relevant for promoting tighter binding between
SIRT1 and the peptide and consequently for the activation of
SIRT1 [23]. Moreover, the slight diﬀerence in binding
aﬃnities previously discussed could rationally explain the
slight reduction, found for NAR, in activating SIRT1 with
respect to RES.
3.2. Antisenescence Eﬀects of SIRT1 Mediated on H9c2 Cells.
The sa-β-Gal staining highlighted that H2O2 60μM was
able to signiﬁcantly induce cellular senescence (Figure 3).
Both NAR 40μM (Figures 3(c) and 3(h)) and RES 25μM
(Figures 3(d) and 3(h)) markedly protected H9c2 from
cell senescence. As expected, the treatment with the acroni-
mous SIR (20μM) evidenced a robust sa-β-Gal staining in
injured cells (Figure 3(e)). Notably, the cotreatments with
NAR plus SIR and RES plus SIR caused the complete loss
of antisenescence properties of polyphenols (Figures 3(f)–
3(h)).
3.3. Cardiometabolic Parameters. Cholesterol, LDL, and non-
LDL levels did not show signiﬁcant changes in the diﬀerent
Table 1: Cardiometabolic parameters measured in the blood. In the table, the cholesterol, LDL, HDL, triglyceride, glycemia, and glycated
haemoglobin levels are reported. The values are expressed as average ± SEM. The number of animals for each treatment group is n = 15.
Statistical analysis is one-way ANOVA followed by Bonferroni’s multiple comparison test (∗p < 0:05; ∗∗p < 0:01). ∗Indicates signiﬁcance
vs. 3-month-old, #indicates signiﬁcance vs. 12-month-old.
3-month-old 6-month-old 12-month-old 12-month-old+NAR 100mg/kg
Total cholesterol (mg/dL) 76 ± 6 70 ± 6 71 ± 3 72 ± 3
Triglycerides (mg/dL) 59 ± 3 66 ± 1 95±15∗∗ 70 ± 5##
HDL (mg/dL) 26 ± 2 19 ± 4 17±1∗∗ 26 ± 3#
LDL (mg/dL) 39 ± 5 38 ± 4 35 ± 3 32 ± 2
Glycemia (mg/dL) 87 ± 14 85 ± 4 103 ± 9 94 ± 7
HbA1C (mmol/mol) 29 ± 1 30 ± 1 29 ± 1 30 ± 1
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Figure 4: The histogram shows cardiovascular risk (measured as
ratio between cholesterol and HDL levels) in 3-, 6-, and 12-month-
old mice and in 12-month-old mice treated with NAR 100mg/kg.
The bars are expressed as average ± SEM. Statistical analysis is
one-way ANOVA followed by Bonferroni’s multiple comparison
test (∗∗p < 0:01). The number of animals for each treatment group
is n = 15. ∗Indicates the signiﬁcance versus 3-month-old mice;
#indicates the signiﬁcance versus 12-month-old mice.
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ages (3, 6, and 12 months); on the other hand, a signiﬁcant
increase of triglyceride levels and a marked reduction of
HDL levels were observed in 12-month-old mice.
NAR treatment was not associated with any variation in
food and water intake if compared with the vehicle group
(data not shown).
Interestingly, the daily treatment with NAR markedly
reduced triglycerides and increased HDL levels in 12-month-
old mice (Table 1). Overall, cardiovascular risk of old mice
was signiﬁcantly lower in NAR-treated animals and it was
similar to that of young controls (Figure 4).
No signiﬁcant changes were observed on glycemic
parameters (glycemia and glycated haemoglobin, Table 1).
3.4. SIRT1 Expression. Myocardial SIRT1 expression showed
an age-related decrease; in particular, no diﬀerences between
young (3-month-old) and young-adult (6-month-old) mice
were shown but a drastic and signiﬁcant reduction of SIRT1
expression (about half) was observed in 12-month-old mice.
Conversely, 12-month-old mice treated with NAR showed a
signiﬁcant increase of SIRT1 levels in cardiac tissue, when
compared with the vehicle-treated mice of the same age. In
agreement with the protein levels, a signiﬁcant increase of
mRNA expression has been also observed in NAR-treated
12-month-old mice if compared with the corresponding con-
trols (Figures 5(a)–5(c)).
3.5. Reactive Oxygen Species Production. DHE staining
highlighted an age-dependent production of ROS. Indeed,
in the hearts from young mice, the DHE-positive areas were
minimal, whereas in 12-month-old mice ROS levels were
markedly higher than young controls. Conversely, in animals
treated with NAR for six months, DHE-positive areas were
signiﬁcantly reduced, showing values superimposable with
the young controls (Figures 6(a) and 6(b)).
3.6. Inﬂammatory Markers. In agreement with the literature,
cardiac levels of two well-known inﬂammatory markers
(TNF-α and IL6) showed an age-dependent increase, thus
indicating a typical chronic low-grade inﬂammation in
senescent tissue; in particular, both TNF-α and IL6 levels
were signiﬁcantly higher in 12-month-old mice than in
young controls. Interestingly, the hearts of mice treated with
NAR had TNF-α and IL6 levels markedly reduced and simi-
lar to those of 3-month-old mice (Figures 7(a) and 7(b)).
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Figure 5: The protein levels of SIRT1 undergo a reduction as a function of increasing age. (a) An example of western blot where a reduction of
SIRT1 levels is visible. At 12 months of age, SIRT1 expression levels are signiﬁcantly lower than those of 3 and 6 months of age. Conversely,
the chronic treatment for 6 months with NAR eﬀectively increases the SIRT1 protein levels, compared to mice of the same age treated with the
vehicle alone. (b) The histogram shows the quantitative analysis executed by densitometry. (c) Relative expression of mRNA SIRT1
normalized vs. the housekeeping gene GAPDH in cardiac tissue from mice fed with NAR (100mg/kg/day) or its vehicle, for 6 months.
The bars are expressed as average ± SEM. Statistical analysis is one-way ANOVA followed by Bonferroni’s multiple comparison test
(∗p < 0:05; ∗∗p < 0:01). The number of animals for each treatment group is n = 5. ∗Indicates the signiﬁcance versus 6-month-old mice;
#indicates the signiﬁcance versus 12-month-old mice.
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3.7. Basal Mitochondrial Membrane Potential. In cardiac iso-
lated mitochondria, a signiﬁcant depolarization of mitochon-
drial potential membrane (ΔΨ) was recorded in 12-month-
old animals (about 9%) vs. the young controls. A trend of
increase was observed in cardiac mitochondria isolated from
mice treated with NAR (Figure 8(a)).
3.8. Citrate Synthase Activity. Citrate synthase (CS) activ-
ity reﬂects metabolic condition of cardiac tissue and, in
our experimental conditions, was 0:42 ± 0:054U/mL in 3-
month-old mice. In cardiac mitochondria isolated from
12-month-old mice, the CS activity was signiﬁcantly lower
(0:29 ± 0:026U/mL) than that in young controls; on the
other side, mitochondria from NAR-treated mice of the
same age showed a signiﬁcantly higher CS activity (0:46 ±
0:058U/mL; Figure 8(b)).
3.9. miR-214-3p Expression. In cardiac tissue of 12-month-
old mice treated with NAR for 6 months, miR-214-3p
expression was signiﬁcantly upregulated (about 7-fold), if
compared to levels of mice treated with vehicle for the same
period (Figure 9).
3.10. Histological Evaluation of Fibrosis. Histological
examination of Mallory trichrome-stained section of heart
ventriculi showed that myocardial ﬁbrosis increases with
age (3 months old: 2:9 ± 0:9%; 6 months old: 1:9 ± 0:9%;
12 months old: 5:6 ± 3:2%). Speciﬁcally, diﬀerences were
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Figure 6: ROS levels in the cellular environment increase proportionally with age. (a) The images show that an increase in DHE-positive
nuclei is obtained with the increase of the age, indicating a higher presence of ROS in the cellular environment, which converts
dihydroethidium into ethidium (bright red nuclei). The treatment with NAR is eﬀective in reducing the number of DHE-positive cells,
indicating a lower concentration of ROS in the cellular environment. (b) The histogram shows the quantiﬁcation of ROS (%). In animals
treated with NAR, ROS levels are signiﬁcantly reduced compared to the group of animals treated with vehicle alone. The bars are
expressed as average ± SEM. Statistical analysis is one-way ANOVA followed by Bonferroni’s multiple comparison test (∗p < 0:05; ∗∗p <
0:01; ∗∗∗p < 0:001). The number of animals for each treatment group is n = 5. ∗Indicates the signiﬁcance versus 3-month-old mice;
#indicates the signiﬁcance versus 12-month-old mice.
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statistically signiﬁcant between 6-month-old mice and 12-
month-old mice. NAR treatment markedly reversed such
an age-dependent ﬁbrotic degeneration (12 months old plus
NAR: 1:5 ± 0:9%); indeed, collagen deposition in the myo-
cardium of 12-month-old NAR-treated mice was statistically
diﬀerent from 12-month-old untreated animals (Figure 10).
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Figure 7: The histograms show (a) the TNF-α levels and (b) the IL6 levels measured in 3-, 6-, and 12-month-old mice and 12-month-old
treated with NAR 100mg/kg mice. Statistical analysis is one-way ANOVA followed by Bonferroni’s multiple comparison test (∗p < 0:05;
∗∗p < 0:01). The number of animals for each treatment group is n = 5. ∗Indicates the signiﬁcance versus 3-month-old mice; #indicates the
signiﬁcance versus 12-month-old mice.
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Figure 8: (a) Change % of the mitochondrial membrane potential observed in 12-month-old mice and in 12-month-old mice treated with
NAR 100mg/kg vs. the young group. The number of animals for each treatment group is n = 6. (b) Citrate synthase activity (U/mL) of 3-
month-old mice, 12-month-old mice, and 12-month-old mice treated with NAR 100mg/kg. The number of animals for each treatment
group is n = 8. ∗Indicates the signiﬁcance versus 3-month-old mice; #indicates the signiﬁcance versus 12-month-old mice. Statistical
analysis is one-way ANOVA followed by Bonferroni’s multiple comparison test (∗p < 0:05).
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4. Discussion
Ageing mediates various structural and functional alterations
in the cardiovascular system. In particular, ﬁbrotic processes,
characterized by the accumulation of collagen type 1 and
amyloid, occur in the myocardium during normal ageing
and lead to myocardial hypertrophy and severe cardiovas-
cular diseases, such as chronic ischemia, cardiomyopathies,
and heart failure [35, 36]. It is also well-known that dur-
ing ageing, a chronic, sterile, and low-grade inﬂammation,
called inﬂammaging, develops and contributes to the path-
ogenesis of age-related diseases [3]. Moreover, SIRT1 levels
and activity decrease with age [9]; hence, considering its
key role in the production of antioxidant defenses, ageing
is unavoidably accompanied with oxidative stress. Moreover,
ageing-associated reduction of SIRT1 leads to the loss of con-
trol on acetylation of target proteins including p53, Nrf2, and
FOXO3, thereby enhancing inﬂammatory, prosenescent, and
apoptotic responses [37].
In this work, no diﬀerence in cardiac SIRT1 expression
has been found between 3-month-old and 6-month-old
mice, whereas a signiﬁcant reduction has been observed in
12-month-old mice; indeed, according to the literature [9],
SIRT1 expression is about halved in 12-month-old animals.
Although murine models are widely used in preclinical
studies to evaluate the human physiology and its modulation,
a number of diﬀerences in the developmental duration and
phases between mice and human have been revealed. There-
fore, a precise correlation between mice age and human age
needs to consider various aspects of the life stages (not only
lifespan but also reproductive age, puberty age, and weaning
period). Indeed, all the proposed methods are not exactly
adequate, and often, more than one method is used. Proba-
bly, the most precise approach for correlating the age of the
mouse with the age of human is to consider the expression
of speciﬁc markers of senescence [38].
At this regard, we observed a marked reduction of cardiac
SIRT1 expression in 12-month-old mice, thus conﬁrming
that the myocardium of this animal group is in a senescence
stage. Moreover, as already published [39], we observed in
this animal group a higher cardiovascular risk and triglycer-
ide levels signiﬁcantly increased if compared with those of 3-
and 6-month-old mice.
Furthermore, an age-dependent production of ROS has
been observed by means of DHE staining; in particular,
extensive positive areas are present in cardiac tissue of 12-
month-old mice, according to the reduction of SIRT1 levels
and, subsequently, of Nrf2-mediated antioxidant defenses.
Moreover, a signiﬁcant increase of the inﬂammatory markers
IL6 and TNF-α has been observed between 3- and 12-month-
old mice.
Finally, the strongest evidence of the myocardial senes-
cence is the ﬁbrotic process. We did not observe changes
between 3- and 6-month-old mice, but a surge of collagen
accumulation has been highlighted in 12-month-old mice;
indeed, an extended area occupied by collagen (about 6%)
has been observed, although this value seems to be particu-
larly variable in relation with individual factors.
Hoppel et al. reported that cardiac mitochondria undergo
detrimental changes during the ageing processes [40]. Mito-
chondria participate in cell bioenergetics and metabolism;
therefore, they play a critical role in lifespan determination
and ageing. The best-known hypothesis to explain ageing is
the free radical theory, and ROS are mainly generated at
the level of the mitochondrial respiratory chain. Hence,
dysfunctional mitochondria produce less ATP and it compro-
mises diﬀerent cellular features [41]. In this context, the most
reliable indicator of mitochondrial eﬃciency is the membrane
potential value that is about -180mV in well-energizing
organelles. However, a mild signiﬁcant depolarization of ΔΨ
is common in mitochondria from elderly individuals; indeed,
although the physiological functions are guaranteed, there is
a lower tolerance toward several types of insults in senescent
myocardium, such as myocardial infarct and heart failure
[42]. At this regard, we observe a partial depolarization
(about 9%) in mitochondria obtained from 12-month-old
mice. This result has been also reported by other researchers,
both at cardiac level and in other organs [43].
Citrate synthase is a mitochondria matrix enzyme that
acts as a rate-limiting enzyme in the ﬁrst step of the Krebs
cycle. It is extensively used as a metabolic marker for evaluat-
ing mitochondrial oxidative capacity [44]. The hearts of 12-
month-old mice present a partially compromised activity of
the citrate synthase enzyme (of about 30%). Taken together,
this experimental evidence demonstrates that the myocar-
dium from 12-month-old mice is in a senescent state and
conﬁrms the reliability of this animal model.
Previous papers of ours reported multiple beneﬁcial
eﬀects of the Citrus ﬂavonoid NAR at the cardiovascular
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Figure 9: Relative expression of miR-214-3p normalized vs. the
housekeeping gene SNORD6 in cardiac tissue from mice fed with
NAR (100mg/kg/day) or its vehicle, for 6 months. All data sets
were represented as the mean ± standard error of mean (SEM).
Comparisons of results between two groups were carried out by
t-test. A p value < 0.05 was considered as statistically signiﬁcant.
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level. We demonstrated vasorelaxant and cardioprotective
properties mediated through the activation of large conduc-
tance calcium-activated potassium channels (BKCa) that
are described both at sarcolemmal and, more recently, at
mitochondrial level [11, 12]. Moreover, unlike the usual car-
dioprotective agents (i.e., diazoxide), NAR guarantees myo-
cardial protection also in mature animals (12-month-old),
suggesting other possible mechanisms involved in its phar-
macological proﬁle [13]. At this regard, Da Pozzo and her
colleagues demonstrated, for the ﬁrst time, antiageing eﬀects
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Figure 10: (a) Mallory trichrome-stained section of heart ventriculi showed in 3-, 6-, and 12-month-old mice and in 12-month-old mice
treated with NAR 100mg/kg. (b) Quantitative analysis of the age-related ﬁbrotic areas. Statistical analysis is one-way ANOVA followed by
Bonferroni’s multiple comparison test (∗p < 0:05; ∗∗p < 0:01; ∗∗∗p < 0:001). The number of animals for each treatment group is n = 5.
∗Indicates the signiﬁcance versus 6-month-old mice; #indicates the signiﬁcance versus 12-month-old mice.
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of NAR in in vitro model, in which senescence has been
induced through a treatment with H2O2 [16].
Interestingly, in the present study, we observed that NAR
activates the isolated SIRT1 enzyme similarly to the reference
activator RES; furthermore, the interaction between NAR
and SIRT1 has been also highlighted by the computational
study. Moreover, in an in vitro model of H2O2-induced cell
senescence, NAR, like RES, showed antisenescence eﬀects
in rat cardiomyoblasts. Interestingly, this eﬀect has been
completely abolished in cells cotreated with the well-known
SIRT1 antagonist SIR, supporting the hypothesis of an
involvement, at least in these experimental conditions, of
SIRT1 in the molecular mechanism of NAR. Furthermore,
a signiﬁcant increase of SIRT1 expression in the myocardium
of animals treated for 6 months with the Citrus ﬂavonoid has
been also observed.
It is well-known that RES, through the activation of
SIRT1, is able to trigger intracellular downstream events that
contribute to the reinforcement of antioxidant defenses and
the mitigation of inﬂammatory processes [45, 46]. Similarly,
NAR markedly reduces cardiac oxidative stress in 12-
month-old mice, restoring the tissue oxidative state to that
of the young control; moreover, NAR restrains the produc-
tion of inﬂammatory markers (IL6 and TNF-α). These results
ﬁnd a conﬁrmation in our very recent paper, in which a sup-
plemental diet with NAR (100mg/kg for 6 months) eﬀec-
tively slowed down oxidative stress associated with retinal
degeneration on rd10 mice [25].
Noteworthly, we observed also an upregulation of miR-
214 in cardiac tissue after NAR treatment. miR-214 is
reported to have cardioprotective activity preventing cell
death and oxidative stress [47, 48]. Moreover, miR-214 has
been also reported to be relevant in age-related diseases, such
as Parkinson; indeed, Wang and colleagues have demon-
strated an overexpression of miR-214 in Parkinson disease
mice treated with RES [49].
Furthermore, levels of miR-214 are decreased in senes-
cent endothelial cells [50] and another ﬂavonoid compound,
luteolin, is able to increase the levels of miR-214 in mesen-
teric arterioles of mice [37]. Intriguingly, miR-214 is also a
regulator of the transcriptional repressor Hypermethylated
In Cancer 1 (HIC1), a predicted target (TargetScanMouse
7.1) of mmu-miR-214-3p, and also a negative regulator of
SIRT1 since it forms a transcriptional repression complex
with SIRT1 deacetylase, and this complex directly binds the
SIRT1 promoter repressing its transcription [51]. Although
further speciﬁc investigations will be aimed at addressing
the miR-214/HIC1/SIRT1 pathway, these preliminary data
strengthen the protective role of NAR.
Furthermore, cardiovascular risk and triglyceride levels
are signiﬁcantly reduced in animals treated with NAR when
compared with animals of the same age. Indeed, it is well-
known that age is a main physiological factor that has a
strong inﬂuence on plasma levels of lipids, and although
the cardiovascular risk is considered a general parameter
indicative of metabolic proﬁle, commonly, it is associated
with a lower tolerance of the myocardium towards cardiovas-
cular insult. Therefore, these results contribute to strengthen
the belief that the Citrus ﬂavanone is endowed with cardio-
protective properties.
NAR improves the ΔΨ value and restores the activity of
citrate synthase enzyme, similarly to those of young ani-
mals, suggesting that it is endowed with beneﬁcial eﬀects
on the mitochondrial eﬃciency and on mitochondrial oxi-
dative capacity.
Further evidence of the antiageing eﬀects of NAR is
obtained by histomorphological analysis; strikingly, NAR
treatment limits the ﬁbrotic areas in the myocardium of 12-
month-old mice, where the percentage of collagen deposits
is similar to that of 3-month-old mice.
5. Conclusions
We demonstrate that NAR, at least in part via, modulation of
SIRT1 enzyme, can slow down the myocardial degradative
processes associated with senescence; and taken together,
these results suggest that a chronic treatment with the Citrus
ﬂavonoid NAR could guarantee beneﬁcial eﬀects at the myo-
cardial level also in humans. A limitation of this study is rep-
resented by the inability to correlate with absolute certainty
the antiageing eﬀects observed in vivo with the presence of
NAR at systemic level. Indeed, on the basis of the results on
the isolated enzyme and on H9c2 cells, we can assert that
SIRT1 is the target of the ageing-preventive eﬀects of NAR;
however, since NAR is converted in several metabolites
in vivo, we cannot exclude the possibility that, at least in part,
the antisenescence proﬁle observed in mice is due to some
active metabolites. In fact, it is well-known that several
NAR metabolites are biologically active, in particular, those
deriving from hydroxylation, methylation, or dehydrogena-
tion, among which hesperetin, apigenin, and eriodictyol
[52]. Moreover, a contribution of intestinal microbiota can-
not be excluded, considering that an amount of short-chain
fatty acids (SCFAs), propionic and acetic acid derivatives,
have been described as metabolism end-products of polyphe-
nols, including Citrus ﬂavonoids [53]. Furthermore, an inter-
esting role of SCFAs in the beneﬁcial eﬀects of ﬂavonoids is
emerging; in particular, they can contribute to the eubiosis
condition and to regulate metabolic processes, also improv-
ing the mitochondrial function [54]. Therefore, future exper-
iments will be certainly directed to examine such aspect.
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